Abstract
Increasing application of nucleic acid vaccines is driving demand for new delivery systems to improve stability and efficacy of DNA vaccines. Solid lipid nanoparticles (SLN) are a particulate carrier system composed of a solid lipid core and a cationic lipid surface suitable for binding negatively charged DNA. SLN delivery systems can be used to bind DNA resulting in an SLN/DNA complex (termed “lipoplex”) which can be used as a potential vaccine.
In this chapter, the methodologies associated with the use of SLNs as a DNA vaccine nanocarrier are discussed. First, requirements for an effective experimental lipoplex vaccine are discussed along with current and historical examples. Then, flowcharts for design and synthesis of lipoplex vaccines are outlined, followed by detailed materials and methods for synthesis and characterization of lipoplex vaccines.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ferraro B, Morrow MP, Hutnick NA et al (2011) Clinical applications of DNA vaccines: current progress. Clin Infect Dis 53(3):296–302. https://doi.org/10.1093/cid/cir334
Dixon AM, Donnelly EC (2011) DNA vaccines: types, advantages, and limitations. Immunology and immune system disorders. Nova Science Publishers, New York
Oyewumi MO, Kumar A, Cui Z (2010) Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines 9(9):1095–1107. https://doi.org/10.1586/erv.10.89
Taki A, Smooker P (2015) Small wonders-the use of nanoparticles for delivering antigen. Vaccines (Basel) 3(3):638–661. https://doi.org/10.3390/vaccines3030638
Penumarthi A, Parashar D, Abraham AN et al (2017) Solid lipid nanoparticles mediate non-viral delivery of plasmid DNA to dendritic cells. J Nanopart Res 19(6). https://doi.org/10.1007/s11051-017-3902-y
Lim M, Badruddoza AZM, Firdous J et al (2020) Engineered nanodelivery systems to improve DNA vaccine technologies. Pharmaceutics 12(1):30. https://doi.org/10.3390/pharmaceutics12010030
Xiao Y, Shi K, Qu Y et al (2019) Engineering nanoparticles for targeted delivery of nucleic acid therapeutics in tumor. Mol Ther Methods Clin Dev 12:1–18. https://doi.org/10.1016/j.omtm.2018.09.002
Mukherjee S, Ray S, Thakur RS (2009) Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci 71(4):349–358. https://doi.org/10.4103/0250-474X.57282
Placzek M, Watrobska-Swietlikowska D, Stefanowicz-Hajduk J et al (2019) Comparison of the in vitro cytotoxicity among phospholipid-based parenteral drug delivery systems: emulsions, liposomes and aqueous lecithin dispersions (WLDs). Eur J Pharm Sci 127:92–101. https://doi.org/10.1016/j.ejps.2018.10.018
de Garibay APR, Solinís MA, del Pozo-Rodríguez A et al (2015) Solid lipid nanoparticles as non-viral vectors for gene transfection in a cell model of Fabry disease. J Biomed Nanotechnol 11(3):500–511. https://doi.org/10.1166/jbn.2015.1968
Azhar Shekoufeh Bahari L, Hamishehkar H (2016) The impact of variables on particle size of solid lipid nanoparticles and nanostructured lipid carriers; a comparative literature review. Adv Pharm Bull 6(2):143–151. https://doi.org/10.15171/apb.2016.021
Baird FJ, Taki AC, Lopata AL et al (2011) DNA vaccines: a modern-day vaccine revolution. Nova Science Publishers, New York
Francis JE, Skakic I, Dekiwadia C et al (2020) Solid lipid nanoparticle carrier platform containing synthetic TLR4 agonist mediates non-viral DNA vaccine delivery. Vaccines (Basel) 8(3):551. https://doi.org/10.3390/vaccines8030551
Rudolph C, Rosenecker J (2012) Formation of solid lipid nanoparticle (SLN)-gene vector complexes for transfection of mammalian cells in vitro. Cold Spring Harb Protoc 2012(3):357–360. https://doi.org/10.1101/pdb.prot068122
Hobernik D, Bros M (2018) DNA vaccines-how far from clinical use? Int J Mol Sci 19(11):3605. https://doi.org/10.3390/ijms19113605
Doroud D, Zahedifard F, Vatanara A et al (2011) Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection. J Control Release 153(2):154–162. https://doi.org/10.1016/j.jconrel.2011.04.011
Koriyama H, Ikeda Y, Nakagami H et al (2020) Development of an IL-17A DNA vaccine to treat systemic lupus erythematosus in mice. Vaccine 8(1):83
Yu J, Tostanoski LH, Peter L et al (2020) DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 369(6505):806–811. https://doi.org/10.1126/science.abc6284
Danaei M, Dehghankhold M, Ataei S et al (2018) Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics 10(2):57
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Francis, J.E., Skakic, I., Smooker, P.M. (2022). Design and Preparation of Solid Lipid Nanoparticle (SLN)-Mediated DNA Vaccines. In: Thomas, S. (eds) Vaccine Design. Methods in Molecular Biology, vol 2412. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1892-9_18
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1892-9_18
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1891-2
Online ISBN: 978-1-0716-1892-9
eBook Packages: Springer Protocols